Overview

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of Small Molecule KIO-301 Administered Intravitreally to Patient s With Retinitis Pigmentosa (ABACUS)

Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
A phase I/II dose-escalating study of the safety, tolerability and efficacy of small molecule KIO-301 administered intravitreally to patient s with retinitis pigmentosa (ABACUS) . Open label.
Phase:
Phase 1
Details
Lead Sponsor:
Kiora Pharmaceuticals, Inc.